Alliance for Regenerative Medicine Announces Agenda for Regen Med Investor Day

– March 13, 2013

Taking place April 17, 2013 in New York City; Agenda includes keynote talks, focused disease sessions with KOL participation and presentations from 16 top regenerative medicine companies

WASHINGTON, DC, March 12, 2013 – The Alliance for Regenerative Medicine (ARM) today announced the agenda for its Regen Med Investor Day, the first investor event organized specifically for the regenerative medicine sector. The event will take place on April 17 at the Harmonie Club, 4 East 60th Street, New York, NY.

This one-day, high-impact program will provide institutional investors and life science analysts with insight from the industry’s leading small- and mid-cap companies as well as exclusive access to regenerative medicine’s top stakeholders.

Credentialed investors, life science strategic partners and members of the media should contact Laura Parsons at if interested in attending.

7:30am           Breakfast & Networking
8:00am           Welcome Remarks
8:10am           Keynote Talk – Kieran Murphy, VP, President & CEO, GE Healthcare Life Sciences
8:30am           Keynote Talk – Jeff Jonas, President, Shire Regenerative Medicine
8:50am           Program Introduction – Jason Kolbert, Senior Biotechnology Analyst, Maxim Group
9:00am           Clinical Outlooks in Cardiovascular Disease
Jason Kolbert, Senior Biotechnology Analyst, Maxim Group (moderator)
Douglas Losordo, MD, Adjunct Professor in Medicine-Cardiology, Northwestern University
Eduardo Marban, MD, Director, Cedars-Sinai Heart Institute
Leslie Miller, MD, Chair, College Of Medicine Dean’s Office, University of South Florida
9:55am           Break
10:10am         Regenerative Medicine in Wound Healing & Tissue Engineering
Ted Tenthoff, Managing Director & Senior Biotechnology Analyst, Piper Jaffray (moderator)
Vincent Falanga, MD, Professor, Boston University School of Medicine
Will Li, MD, President & Medical Director, The Angiogenesis Foundation
Thomas Serena, MD, FACS, CEO and Medical Director SerenaGroup
11:05am         Therapeutics for a Broad Range of CNS Diseases
Ren Benjamin, Ph.D., Managing Director & Senior Biotechnology Analyst, Burrill & Company (moderator)
Sean Savitz, MD, Professor of Neurology, University of Texas Medical School, UTHealth
12:00pm         Plated Lunch & Networking
12:45pm         Lunchtime Presentation – G. Steven Burrill, CEO, Burrill & Company
1:00pm           Cytori Therapeutics – Chris Calhoun, CEO
1:15pm           Athersys – Gil Van Bokkelen, Chairman & CEO
1:30pm           Mesoblast – Silviu Itescu, CEO & President
1:45pm           Juventas Therapeutics – Rahul Aras, President & CEO
2:00pm           Aastrom Biosciences – Dan Orlando, Chief Commercial Officer
2:15pm           NeoStem – Robin Smith, Chairman & CEO
2:30pm           Pluristem Therapeutics – Zami Aberman, Chairman & CEO
2:45pm           Cytomedix – Martin Rosendale, CEO
3:00pm           Afternoon Break
3:15pm           Sangamo BioSciences – Edward Lanphier, President & CEO
3:30pm           BioTime Acquisition Corp – Thomas Okarma, President & CEO
3:45pm           Advanced Cell Technology (ACT) – Gary Rabin, Chairman & CEO
4:00pm           StemCells Inc. – Martin McGlynn, President & CEO
4:15pm           Organogenesis – Geoff MacKay, President & CEO
4:30pm           Organovo – Keith Murphy, CEO
4:45pm           Tigenix – Eduardo Bravo, CEO
5:00pm           Mimedx – Michael Senken, CFO
5:15pm           Program Wrap-up – Ted Tenthoff, Managing Director & Senior Biotechnology Analyst, Piper Jaffray
5:30pm           Networking Reception

This meeting is co-hosted by leading financial firms Burrill & Company, Piper Jaffray and Maxim Group and in partnership with Life Science Advisors and Blaise Group International.

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit
# # #